Enlivex Therapeutics

Enlivex is an Israeli-based cellular immunotherapy company founded in October 2005 by Professor Dror Mevorach, a world-renowned expert in the clearance of dead (apoptotic) cells. Enlivex is developing both autologous and allogeneic drug pipelines for the treatment of autoimmune and inflammatory conditions such as graft-versus-host disease (GvHD), solid organ transplant rejection, Crohn's disease, and other autoimmune and inflammatory diseases.